Meeting
2024 ASCO Annual Meeting
Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.
Authors
John M. Wrangle
Medical University of South Carolina, Charleston, SC
John M. Wrangle , Mary Weber Redman , Hatim Husain , Karen L. Reckamp , Tom Stinchcombe , Martin Joseph Edelman , Ticiana Leal , Bryan A. Faller , Katherine Minichiello , Hossein Borghaei , Karen Kelly , Roy S. Herbst , Jhanelle E. Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT05096663
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2619)
DOI
10.1200/JCO.2024.42.16_suppl.2619
Abstract #
2619
Poster Bd #
98
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.
First Author: Emiliano Calvo
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.
First Author: Ulka N. Vaishampayan
Poster
2021 ASCO Annual Meeting
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
First Author: Mariam Jamal-Hanjani
Poster
2018 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
First Author: Andreas Nicholas Saltos